Inactive Instrument

Mymetics Corporation Stock Other OTC

Equities

MYMX

US62856A1025

Biotechnology & Medical Research

Sales 2021 430K 458K Sales 2022 1.03M 1.1M Capitalization 8.51M 9.07M
Net income 2021 -4M -4.26M Net income 2022 -4M -4.26M EV / Sales 2021 177 x
Net Debt 2021 67.1M 71.51M Net Debt 2022 71.68M 76.4M EV / Sales 2022 78 x
P/E ratio 2021
-1.86 x
P/E ratio 2022
-1.77 x
Employees -
Yield 2021 *
-
Yield 2022
-
Free-Float 48.72%
More Fundamentals * Assessed data
Dynamic Chart
Mymetics Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Mymetics Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Mymetics Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Mymetics Corporation Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Mymetics Corporation Auditor Raises 'Going Concern' Doubt CI
Mymetics Corporation Appoints Marcel B. Rüegg to the Board CI
Mymetics Corporation Announces Resignation of Ernest M. Stern as A Member of the Board of Directors CI
Mymetics Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Mymetics Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
Mymetics Corporation Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Mymetics Corporation Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Mymetics Corporation Auditor Raises 'Going Concern' Doubt CI
Mymetics Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021 CI
Mymetics Corporation Reports Earnings Results for the Second Quarter Ended June 30, 2021 CI
Mymetics Corporation Reports Earnings Results for the First Quarter Ended March 31, 2021 CI
More news
Managers TitleAgeSince
Chief Executive Officer 56 09-06-30
Corporate Officer/Principal - -
Members of the board TitleAgeSince
Director/Board Member 76 07-07-01
Director/Board Member 63 12-03-22
Director/Board Member - 23-01-15
More insiders
Mymetics Corporation is a vaccine company. The Company is focused on developing vaccines for infectious diseases. The Company has over five vaccine candidates in its pipeline: human immunodeficiency virus type 1 (HIV-1)/acquired immune deficiency syndrome (AIDS), intra nasal Influenza, Malaria, Herpes Simplex Virus (HSV) and the Respiratory Syncitial Virus (RSV) vaccine. Its technology utilizes virosomes, lipid-based carriers containing functional fusion viral proteins and natural membrane proteins, in combination with rationally designed antigens. Its prophylactic HIV-1 vaccine candidate is constituted of virosomes linked to conserved antigens derived from the HIV-1 glycoprotein 41 (gp41) proteins from the clade B. The RSV vaccine consists of the reconstituted membrane of RSV containing the native viral proteins. The HSV vaccine candidate consists of the reconstituted membrane of HSV-1 or HSV-2. The intranasal influenza vaccine includes the reconstituted membrane of influenza virus.
More about the company